Heard a distant ROR; now getting a bit closer?

[gemit2000]

[open post]

Patient Power featured Dr. Kipps discussing cirmtuzumab, a mAb that attaches to ROR1 protein to suppress signaling used by CLL cells.

patientpower.info/video/loo...

It reminded me how I first read about ROR1 on Chaya Venkat's site where she explained how unlike new therapies targeting CD19 or CD20 on B-Cells, any targeting ROR1 would have the advantage of only attaching to CLL cells as ROR1 existed only on embryonic cells or cancer cells.

She mentioned early CAR T research at MD Anderson that was attempting to target ROR1 (rather than the CD19 as pioneered at UPenn by Dr. June). Appealed to my common sense - if it only targeted cancer cells, that's better, no?

Does anyone know of other similar research/trials with a ROR1 focus? I googled a bit and could only find a 2014 MD Anderson newsletter discussing such research under the subheading - Adoptive Immunotherapy with Genetically Modified T cells (CAR therapy).

mdanderson.org/documents/De... -

So is cirmtuzumab the only Tx currently with a ROR1 focus? Is the MDA CAR T research still viable? Or perhaps there's similarly focused targeted oral inhibitors in development?

Thanks, Gene

[Cllcanada Top Poster CURE Hero]

There are a couple of drugs in development, here is one

mb.cision.com/Main/1190/236...

[gemit2000 in reply to Cllcanada]

Thanks Chris. Do you know why the paucity of research in this area? Even the company you highlight is still at the rodent phase. Like what happened to MDA research from 2014? Perhaps approaches targeting ROR1 experience some major obstacles or challenges? Otherwise always thought this would have been the most sought after strategy.

[Cllcanada Top Poster CURE Hero in reply to gemit2000]

MDA enrolled a patient, but I have heard nothing else.. maybe things went sideways... they seem transfixed on CAR NK at the moment

[81ue]

interesting, Cirmtuzumab UCSD

clinicaltrials.gov/ct2/show...

estimated study completion date is December 2018

[Justasheet1 in reply to 81ue]

The phase 1 and 2 dosing of cirmtuzamab is completed.

The new trial is Ibrutinib plus cirmtuzamab. Available also at MDA